Evidence map›Paper›PMID 26173102›Full record

ArticleThe Journal of urology2015

Genetic Variants in the Wnt/β-Catenin Signaling Pathway as Indicators of Bladder Cancer Risk.

Jeanne A Pierzynski, Michelle A Hildebrandt, Ashish M Kamat, Jie Lin, Yuanqing Ye, Colin P N Dinney, Xifeng Wu

Open access · greenAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in The Journal of urology, 2015. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 28 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
28citing papers in PubMed, 1 pooled it
2.7field-weighted citation impact, top 10% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

28 citing papers in PubMed, 1 synthesis or guideline pooled it, 68 citations in OpenAlex.

  1. Pooled it
  2. Review
  3. Review
  4. Article
  5. Article
  6. Article
  7. Review
  8. Article
  9. Article
  10. Article
  11. Review
  12. Review
  13. Review
  14. Review
  15. Article
  16. Article
  17. Article
  18. Review
  19. Article
  20. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

7 authors at 1 institution in 1 country.

Jeanne A PierzynskiDepartment of Epidemiology and Division of Surgery, Department of Urology (AMK, CPND), University of Texas M.D. Anderson Cancer Center, Houston, Texas.
Michelle A HildebrandtDepartment of Epidemiology and Division of Surgery, Department of Urology (AMK, CPND), University of Texas M.D. Anderson Cancer Center, Houston, Texas.
Ashish M KamatDepartment of Epidemiology and Division of Surgery, Department of Urology (AMK, CPND), University of Texas M.D. Anderson Cancer Center, Houston, Texas.
Jie LinDepartment of Epidemiology and Division of Surgery, Department of Urology (AMK, CPND), University of Texas M.D. Anderson Cancer Center, Houston, Texas.
Yuanqing YeDepartment of Epidemiology and Division of Surgery, Department of Urology (AMK, CPND), University of Texas M.D. Anderson Cancer Center, Houston, Texas.
Colin P N DinneyDepartment of Epidemiology and Division of Surgery, Department of Urology (AMK, CPND), University of Texas M.D. Anderson Cancer Center, Houston, Texas.
Xifeng WuDepartment of Epidemiology and Division of Surgery, Department of Urology (AMK, CPND), University of Texas M.D. Anderson Cancer Center, Houston, Texas. Electronic address: xwu@mdanderson.org.
The University of Texas MD Anderson Cancer Center · US

Funding

Targeting Ral GTPases in Bladder CancerP50CA091846 · NCI · UNIVERSITY OF TX MD ANDERSON CAN CTR · PI DINNEY, COLIN P.N., MCCONKEY, DAVID J. · 2001 to 2018
$37.4M
Genome-Wide Association Analysis of Bladder CancerU01CA127615 · NCI · UNIVERSITY OF TX MD ANDERSON CAN CTR · PI WU, XIFENG · 2008 to 2012
$5.1M
Markers of Genetic Susceptibility to Bladder CancerR01CA074880 · NCI · UNIVERSITY OF TX MD ANDERSON CAN CTR · PI WU, XIFENG · 1999 to 2008
$3.1M
NCI NIH HHS P50 CA091846NCI NIH HHS P50 CA91846NCI NIH HHS R01 CA074880NCI NIH HHS U01 CA127615
6 · The paper itself

Abstract

purposeGenetic factors that influence bladder cancer risk remain largely unknown. Previous research has suggested that there is a strong genetic component underlying the risk of bladder cancer. The Wnt/β-catenin signaling pathway is a key modulator of cellular proliferation through its regulation of stem cell homeostasis. Furthermore, variants in the Wnt/β-catenin signaling pathway have been implicated in the development of other cancers, leading us to believe that this pathway may have a vital role in bladder cancer development. MATERIALS AND

methodsA total of 230 single nucleotide polymorphisms in 40 genes in the Wnt/β-catenin signaling pathway were genotyped in 803 bladder cancer cases and 803 healthy controls.

resultsA total of 20 single nucleotide polymorphisms were nominally significant for risk. Individuals with 2 variants of LRP6: rs10743980 were associated with a decreased risk of bladder cancer in the recessive model in the initial analysis (OR 0.76, 95% CI 0.58-0.99, p=0.039). This was validated using the bladder genome-wide association study chip (OR 0.51, 95% CI 0.27-1.00, p=0.049 and for combined analysis p=0.007).

conclusionsTogether these findings implicate variants in the Wnt/β-catenin stem cell pathway as having a role in bladder cancer etiology.

Indexed as

AgedAged, 80 and overbeta CateninCell Transformation, NeoplasticFemaleGenetic Predisposition to DiseaseGenetic VariationGenotypeHumansMaleMiddle AgedPolymorphism, Single NucleotideReference ValuesUrinary BladderUrinary Bladder NeoplasmsWnt Signaling Pathwaybeta CateninCTNNB1 protein, humanbeta cateninpolymorphismrisksingle nucleotideurinary bladder neoplasmsWnt signaling pathway

Identifiers

PMID26173102
PMCPMC5087323
OpenAlexW1476363707

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.